Patents Assigned to Takeda Pharmaceutical Company Limted
  • Publication number: 20200140505
    Abstract: The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P2?? (I) wherein each symbol is as defined herein.
    Type: Application
    Filed: August 29, 2019
    Publication date: May 7, 2020
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMTED
    Inventors: TAIJI ASAMI, NAOKI NISHIZAWA, AYUMU NIIDA, YOKO KANEMATSU, MARI ADACHI, SHIRO TAKEKAWA, TOMOKO MORIMOTO
  • Patent number: 9073864
    Abstract: Provided is an aromatic ring compound having a glucagon antagonistic action, which is useful for the prophylaxis or treatment of diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof has a superior glucagon antagonistic action, and is useful as a glucagon antagonist, a glucose production inhibitor or an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: July 7, 2015
    Assignee: Takeda Pharmaceutical Company Limted
    Inventors: Minoru Sasaki, Hideki Furukawa, Kousuke Hidaka, Kyoko Toyofuku, Takatoshi Yogo, Toshiki Murata
  • Patent number: 8470837
    Abstract: Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using the presently described compounds.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: June 25, 2013
    Assignee: Takeda Pharmaceutical Company Limted
    Inventors: Qing Dong, Stephen W. Kaldor
  • Publication number: 20110172249
    Abstract: The present invention provides a method for improving absorbability of the active ingredient of an enteric polymer coated preparation, which includes using an organic acid.
    Type: Application
    Filed: September 2, 2009
    Publication date: July 14, 2011
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMTED
    Inventors: Kazuhisa Kamikawa, Takayuki Okabe, Miho Nakamura
  • Patent number: 7825242
    Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound of the formula: wherein R2 is amino (C1-6)alkyl, hetero(C3-12)cycloakyl, hetero(C4-12)bicycloaryl, heteroaryl, or cyano; and W, X, Y, Z, R1, R5 and R7 are as defined herein.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: November 2, 2010
    Assignee: Takeda Pharmaceutical Company Limted
    Inventors: Jun Feng, Stephen L. Gwaltney, Betty Lam, Zhiyuan Zhang
  • Publication number: 20100029619
    Abstract: The present invention provides a compound represented by the formula (I): wherein ring A is a ring which is optionally further substituted; R1 is a hydrogen atom or a substituent; R2 is a hydrogen atom or a substituent; R3 is a hydrogen atom or a substituent; R4 is a hydrogen atom or a substituent; R5 is a hydrogen atom or a substituent; R6 is a hydrogen atom or a substituent; X is ?N— or ?C(Z)- (Z is a hydrogen atom or a substituent); when X is ?C(Z)-, Z and R6 are optionally bonded to each other to form, together with the carbon atom bonded thereto, an optionally substituted ring, provided that when X is ?CH—, then R6 is not optionally substituted 2-piperidinyl, excluding N-imidazo[1,2-a]pyridin-2-yl-4-methyl-benzamide, N-imidazo[1,2-a]pyridin-2-yl-benzamide and N-(7-methylimidazo[1,2-a]pyridin-2-yl)-benzamide, or a salt thereof, and a pharmaceutical agent containing same.
    Type: Application
    Filed: August 3, 2007
    Publication date: February 4, 2010
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMTED
    Inventors: Osamu Uchikawa, Nozomu Sakai, Yoshito Terao, Hideo Suzuki
  • Publication number: 20090275591
    Abstract: The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R2 is an optionally substituted C6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R3 and R4 are each a hydrogen atom, or one of R3 and R4 is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R5 is an alkyl group or a salt thereof.
    Type: Application
    Filed: August 29, 2006
    Publication date: November 5, 2009
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMTED
    Inventors: Masahiro Kajino, Atsushi Hasuoka, Haruyuki Nishida
  • Publication number: 20090270625
    Abstract: The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein R1 is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6 is (cyclic group optionally having substituent(s))-carbonyl, and the like; R7, R8, R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; — --- represents unsubstituted (i.e., absence) or a single bond; and represents a single bond or a double bond, or a salt thereof, and the like.
    Type: Application
    Filed: June 2, 2009
    Publication date: October 29, 2009
    Applicant: Takeda Pharmaceutical Company Limted
    Inventors: Masahiro Kajino, Nicholas William Hird, Naoki Tarui, Hiroshi Banno, Yasuhiko Kawano, Nobuhiro Inatomi